Posters

    Mechanistic Network Models In Safety And Toxicity Evaluation Of Nutraceuticals

    Gonzalez-Suarez, I.; Marescotti, D.; Acali, S.; Johne, S. Johne.; Martin, F.; Dulize, R.; Baumer, K.; Peric, D.; Guedj, E.; Frentzel, S.; Mathis, C.; Ivanov, N. V.; Hoeng, J.; Peitsch, M. C.
    Conference date
    Mar 23, 2015
    Conference name

    Society of Toxicology (SOT) 2015
    Link to more information
    Topic
    Summary

    Nutraceuticals are food constituents with potential health benefits beyond their nutritional value. In vitro and In vivo studies suggest a protective effect of nutraceuticals against chronic diseases, but the results are not fully supported by clinical evidence. Nutraceuticals are generally recognized as safe at dietary doses; however, they are often consumed at higher doses in the form of nutritional supplements. Exposure to supra-dietary doses of nutraceuticals is of toxicological concern, particularly because some substances may cause genomic changes in target tissues. Here, we assessed the effect of four nutraceuticals, resveratrol (a polyphenol present in grapes and berries), quercetin (a flavonol found in many fruits, vegetables, leaves and grains), astaxanthin (a keto-carotenoid found in microalgae, yeast, many fishes and crustaceans), and epigallocatechin gallate (a polyphenol present in tea and in various vegetables), in two human primary cell types, cryopreserved hepatocytes and coronary artery endothelial cells (HCAECs), using a multi-step systems biology approach combining (STEP 1) real-time cell viability measurements with (STEP 2) a panel of high-content screening (HCS) endpoints and (STEP 3) gene expression changes analysis based on computable biological network models.  

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.